Riesgo cardiovascular en pacientes con crisis gotosa: ¿existe alguna  asociación y necesidad de tratamiento?

Yelson Alejandro Picón-Jaimes; Manuel Alejandro Merchán-Cepeda; Juan Camilo Castro-Córdoba; Manuel Alejandro Jaramillo-Acosta; Hector Jaime Peñaranda-Ocampo

doi:10.47487/apcyccv.v3i4.240

Authors

Yelson Alejandro Picon-Jaimes Programa de Doctorado en Salud, Bienestar y Bioética, Universidad Ramón Llul. Barcelona, España. https://orcid.org/0000-0002-7498-5346
Manuel Alejandro Merchan-Cepeda Departamento de Medicina, Fundación Universitaria Ciencias de la Salud. Bogotá, Colombia. https://orcid.org/0000-0003-3933-3876
Juan Camilo Castro-Cordoba Departamento de Medicina, Universidad Antonio Nariño. Bogotá, Colombia. https://orcid.org/0000-0002-2387-841X
Manuel Alejandro Jaramillo-Acosta Departamento de Medicina, Universidad del Quindío. Armenia, Colombia. https://orcid.org/0000-0002-0599-5014
Hector Jaime Peñaranda-Ocampo Departamento de Medicina, Universidad Libre. Cali, Colombia. https://orcid.org/0000-0002-7479-3539

DOI:

https://doi.org/10.47487/apcyccv.v3i4.240

Keywords:

Gout, Heart Disease Risk Factors

Downloads

Download data is not yet available.

References

Organización Mundial de la Salud. Enfermedad Cardiovascular [Internet]. Ginebra: OMS; c2022 [citado el 26 de noviembre de 2022]. Disponible en: https://www.who.int/health-topics/cardiovasculardiseases#tab=tab_1

Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-390. doi: 10.1038/s41584-020-0441-1.

Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA. 2022;328(5):440-450. doi: 10.1016/j.rec.2016.05.009.

Saag KG, Becker MA, White WB, Whelton A, Borer JS, Gorelick PB, et al. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022;74(9):1593-1601. doi: 10.1002/art.42160.

Wang M, Zhang Y, Zhang M, Li H, Wen C, Zhao T, et al. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and metaanalysis. Ann Palliat Med. 2021;10(10):10327-10337. doi: 10.21037/apm-21-1564.

Roth ME, Chinn ME, Dunn SP, Bilchick KC, Mazimba S. Association of colchicine use for acute gout with clinical outcomes in acute decompensated heart failure. Clin Cardiol. 2022;45(7):733-741. doi: 10.1002/clc.23830.

Lim GB. Gout flares can precede cardiovascular events. Nat Rev Cardiol. 2022;19(10):642. doi: 10.1038/s41569-022-00766-x.

Lozada-Martínez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for ecoepidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022;99:106589. doi: 10.1016/j.ijsu.2022.106589.

Pérez-Fontalvo NM, De Arco-Aragón MA, Jimenez-García JDC, Lozada-Martinez ID. Molecular and computational research in lowand middle-income countries: Development is close at hand. J Taibah Univ Med Sci. 2021;16(6):948-949. doi: 10.1016/j.jtumed.2021.06.010